Expanding Heart Transplant in the Era of Direct-Acting Antiviral Therapy for Hepatitis C-Reference-Cited by-同舟云学术

Expanding Heart Transplant in the Era of Direct-Acting Antiviral Therapy for Hepatitis C

Published:2020-02-01 Issue:2 Volume:5 Page:167
ISSN:2380-6583
Container-title:JAMA Cardiology
language:en
Short-container-title:JAMA Cardiol

Author:

Schlendorf Kelly H.¹,Zalawadiya Sandip¹,Shah Ashish S.¹,Perri Roman¹,Wigger Mark¹,Brinkley D. Marshall¹,Danter Matthew R.¹,Menachem Jonathan N.¹,Punnoose Lynn R.¹,Balsara Keki¹,Sacks Suzanne Brown¹,Ooi Henry¹,Awad Joseph A.¹,Sandhaus Emily¹,Schwartz Christopher¹,O’Dell Heather¹,Carver Alicia B.¹,Edmonds Cori L.¹,Ruzevich-Scholl Shelley¹,Lindenfeld JoAnn¹

Affiliation:

1. Vanderbilt University Medical Center, Nashville, Tennessee

Publisher

American Medical Association (AMA)

Subject

Cardiology and Cardiovascular Medicine

Link

https://jamanetwork.com/journals/jamacardiology/articlepdf/2757048/jamacardiology_schlendorf_2019_oi_190084.pdf

Reference24 articles.

1. Hepatitis C virus seropositivity in organ donors and survival in heart transplant recipients.;Gasink;JAMA,2006

2. Donor hepatitis-C seropositivity is an independent risk factor for the development of accelerated coronary vasculopathy and predicts outcome after cardiac transplantation.;Haji;J Heart Lung Transplant,2004

3. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.;Afdhal;N Engl J Med,2014